TENK
TenX Keane Acquisition

407
Mkt Cap
$90.73M
Volume
1.01M
52W High
$6.19
52W Low
$0.5506
PE Ratio
-6.09
TENK Fundamentals
Price
$1.16
Prev Close
$1.07
Open
$1.06
50D MA
$1.44
Beta
-2.39
Avg. Volume
245,813.21
EPS (Annual)
-$0.3108
P/B
2.56
Loading...
Loading...
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Citius Oncology Inc.?
What is the 52-week high for Citius Oncology Inc.?
What is the 52-week low for Citius Oncology Inc.?
What is Citius Oncology Inc. stock price today?
What was Citius Oncology Inc. stock price yesterday?
What is the PE ratio of Citius Oncology Inc.?
What is the Price-to-Book ratio of Citius Oncology Inc.?
What is the 50-day moving average of Citius Oncology Inc.?

Latest TENK News

View
No TENK news at the moment.

Advertisement|Remove ads.

Advertisement|Remove ads.